madman
Super Moderator
* Given emerging data on sarcopenia and GLP-1 RAs, future studies should investigate the potential role of combined GLP-1 and testosterone therapies to optimize outcomes in body composition, metabolic control, and sexual health.
Table 1. Impact of GLP-1 Receptor Agonist Therapy on Testosterone Levels, Sexual Healthm and Metabolic parameters in Men with Obesity or Type 2 Diabetes: Summary statistics
PRELIMINARY ASSESSMENT OF GLP-1 RECEPTOR AGONISTSON TESTOSTERONE LEVELS, ERECTILE FUNCTION, ANDMETABOLIC OUTCOMES IN MEN WITH OBESITY OR TYPE 2DIABETES
Nathalie Eid*, Vanessa Soriano, Kristyn Williams, Michael Natter,Michael Weintraub, Hossein Sadeghi-Nejad, New York, NY
INTRODUCTION AND OBJECTIVE
Glucagon-like peptide-1receptor agonists (GLP-1 RAs) have benefits in glycemic control and weight reduction. Emerging research also suggests benefits in male reproductive health, including improvements in testosterone (T) levels and erectile function. However, new studies highlight that GLP-1 RAs may induce significant loss of lean body mass, or sarcopenia. Given that T can support muscle maintenance, our study seeks to explore the interplay between GLP-1 therapy and T levels, as well as provide preliminary insights into their impact on sexual function.
METHODS
A retrospective chart review was conducted on 53 male patients prescribed GLP-1 RAs for type 2 diabetes (T2DM) or obesity. Data collected included demographics, smoking status, ndications for GLP-1 RA, hypogonadism diagnosis, T replacementt herapy usage, erectile dysfunction medication use, weight, BMI, HbA1c, and total and free T (pre- and post-therapy). Analyses were performed with SPSS 29 (IBM Corp., Armonk, NY).
RESULTS
Results are summarized in Table 1. The mean baseline BMI was 35.56, with 64% of patients with obesity. The mean baseline HbA1c was 6.43, with 36% with prediabetes and 40% with T2DM. Patients showed a mean increase of 111 ng/dL in total T. A paired t-test comparing pre- and post-testosterone levels showed a statistically significant improvement (t= -2.19, p= 0.048). The mean SHIM score increased by 2.4; however, individual patient scores demonstrated variability. The Wilcoxon signed-rank test for SHIM scores yielded no significant difference pre- and post therapy (W= 10.5, p= 0.42). Regression analysis revealed no significant relationship between weight change and testosterone levels (R-squared = 0.000, p= 0.969), with a regression coefficient of -0.1020.
CONCLUSIONS
GLP-1 RA therapy is associated with significant increases in T among men with obesity or T2DM. The lack of a significant association between weight loss and T change suggests that the underlying mechanisms may be independent of weight loss.While preliminary data showed improvements in erectile function, additional data will be necessary to determine whether these trends will achieve clinical or statistical significance. Given emerging data on sarcopenia and GLP-1 RAs, future studies should investigate the potential role of combined GLP-1 and testosterone therapies to optimize outcomes in body composition, metabolic control, and sexual health.
Table 1. Impact of GLP-1 Receptor Agonist Therapy on Testosterone Levels, Sexual Healthm and Metabolic parameters in Men with Obesity or Type 2 Diabetes: Summary statistics
PRELIMINARY ASSESSMENT OF GLP-1 RECEPTOR AGONISTSON TESTOSTERONE LEVELS, ERECTILE FUNCTION, ANDMETABOLIC OUTCOMES IN MEN WITH OBESITY OR TYPE 2DIABETES
Nathalie Eid*, Vanessa Soriano, Kristyn Williams, Michael Natter,Michael Weintraub, Hossein Sadeghi-Nejad, New York, NY
INTRODUCTION AND OBJECTIVE
Glucagon-like peptide-1receptor agonists (GLP-1 RAs) have benefits in glycemic control and weight reduction. Emerging research also suggests benefits in male reproductive health, including improvements in testosterone (T) levels and erectile function. However, new studies highlight that GLP-1 RAs may induce significant loss of lean body mass, or sarcopenia. Given that T can support muscle maintenance, our study seeks to explore the interplay between GLP-1 therapy and T levels, as well as provide preliminary insights into their impact on sexual function.
METHODS
A retrospective chart review was conducted on 53 male patients prescribed GLP-1 RAs for type 2 diabetes (T2DM) or obesity. Data collected included demographics, smoking status, ndications for GLP-1 RA, hypogonadism diagnosis, T replacementt herapy usage, erectile dysfunction medication use, weight, BMI, HbA1c, and total and free T (pre- and post-therapy). Analyses were performed with SPSS 29 (IBM Corp., Armonk, NY).
RESULTS
Results are summarized in Table 1. The mean baseline BMI was 35.56, with 64% of patients with obesity. The mean baseline HbA1c was 6.43, with 36% with prediabetes and 40% with T2DM. Patients showed a mean increase of 111 ng/dL in total T. A paired t-test comparing pre- and post-testosterone levels showed a statistically significant improvement (t= -2.19, p= 0.048). The mean SHIM score increased by 2.4; however, individual patient scores demonstrated variability. The Wilcoxon signed-rank test for SHIM scores yielded no significant difference pre- and post therapy (W= 10.5, p= 0.42). Regression analysis revealed no significant relationship between weight change and testosterone levels (R-squared = 0.000, p= 0.969), with a regression coefficient of -0.1020.
CONCLUSIONS
GLP-1 RA therapy is associated with significant increases in T among men with obesity or T2DM. The lack of a significant association between weight loss and T change suggests that the underlying mechanisms may be independent of weight loss.While preliminary data showed improvements in erectile function, additional data will be necessary to determine whether these trends will achieve clinical or statistical significance. Given emerging data on sarcopenia and GLP-1 RAs, future studies should investigate the potential role of combined GLP-1 and testosterone therapies to optimize outcomes in body composition, metabolic control, and sexual health.
